People · Operator

John Wells

Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Retailing

2
Companies
8
Filings
$14.6M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Luminary Therapeutics, Inc.BiotechnologySeries A$14.5M$4.0M2021
Westco, LlcRetailingPre-Seed$100K$785K2011
Operator network

John Wells at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Jeff Ross · 4 companies · 1 sharedJeff RossJeff Liter · 3 companies · 1 sharedJeff LiterJohn Hurley · 3 companies · 1 sharedJohn HurleyBranden Moriarity · 2 companies · 1 sharedBranden MoriarityDavid Largaespada · 2 companies · 1 sharedDavid LargaespadaAlexander Naydich · 1 companies · 1 sharedAlexander NaydichGeorge Cox · 1 companies · 1 sharedGeorge CoxJames Haymaker · 1 companies · 1 sharedJames HaymakerJim Haymaker · 1 companies · 1 sharedJim HaymakerMark Chance · 1 companies · 1 sharedMark ChancePeter Kosa · 1 companies · 1 sharedPeter KosaTracey Lodie · 1 companies · 1 sharedTracey LodieMARSHALL COLE · 3 companies · 1 sharedMARSHALL COLEPressley Stutts · 1 companies · 1 sharedPressley StuttsLuminary Therapeutics, Inc. · $14.5M raisedLuminary Therapeutics…Westco, Llc · $0.1M raisedWestco, LlcJohn WellsJW
John Wells Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside John Wells on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Jeff Ross14
John Hurley13
MARSHALL COLE13
Jeff Liter13
David Largaespada12
Branden Moriarity12
James Haymaker11
Pressley Stutts11
Mark Chance11
Peter Kosa11
George Cox11
Jim Haymaker11
Alexander Naydich11
Tracey Lodie11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.